IBEX Technologies Inc. (IBT.V)
| Previous Close | 0.6000 |
| Open | 0.6000 |
| Bid | 0.5500 x 0 |
| Ask | 0.5700 x 0 |
| Day's Range | 0.6000 - 0.6000 |
| 52 Week Range | 0.2700 - 0.6400 |
| Volume | |
| Avg. Volume | 9,836 |
| Market Cap | 14.894M |
| Beta (5Y Monthly) | 0.25 |
| PE Ratio (TTM) | 10.00 |
| EPS (TTM) | 0.0600 |
| Earnings Date | Nov 09, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
IBEX Technologies Announces Normal Course Issuer Bid
MONTREAL, Aug. 02, 2022 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today announced that the TSX Venture Exchange (“TSXV”) has approved IBEX’s normal course issuer bid (“NCIB”). Under the NCIB, IBEX may purchase for cancellation a maximum of 1,800,000 common shares, representing approximately 9.9% of the 18,198,067 shares forming IBEX’s public float. The shares may be purchased through the facilities of the TSXV. The NCIB will commence on August 5, 202
- Simply Wall St.
Are IBEX Technologies Inc.'s (CVE:IBT) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
With its stock down 31% over the past three months, it is easy to disregard IBEX Technologies (CVE:IBT). But if you pay...
- GlobeNewswire
IBEX Reports Results for the Third Quarter and the Nine Months Ended April 30, 2022
MONTRÉAL, Québec, June 10, 2022 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the nine months ended April 30, 2022. “We are pleased with the continued growth in sales, driven by strong sales of heparinase-based products, as well as by the sales of aryl-acyl amidase, a product used in tests for acetaminophen poisoning; and also with the continued strengthening of the Company’s balance sheet” said Paul Baehr, IBEX P
